



Search News:

April 09, 2013 06:13 AM Eastern Daylight Time

Alitair Offers Two Ion-Exchange Resin Patents at a Sealed Bid Sale

MORRISTOWN, N.J.--(BUSINESS WIRE)--Alitair Pharmaceuticals, Inc., an early stage pharmaceutical company with multiple respiratory product candidates in development, today announced that it has retained Finn, Warnke & Gayton, LLP ("FWG"), to sell two Alitair patents and an associated royalty stream at a sealed bid sale on May 24, 2013.

The first patent was issued in 2012 and covers the use of ion exchange resins in immediate-release and extended-release solid oral dosage forms. The second patent was issued in 2013 and covers the use of ion exchange resins in immediate-release and extended-release oral solid formulations of benzonatate, a non-narcotic prescription cough product. The royalty stream includes milestone payments and has an estimated net present value of \$7.5 million.

Either or both of the patents and the royalty stream will be sold at the sealed bid sale on Friday, May 24, 2013, at noon. Anyone interested in bidding must sign a Confidential Disclosure Agreement ("CDA") to obtain a bid package. Contact Chris Finn of FWG at cfinn@finnwarnkegayton.com or 781-237-8840 to obtain a CDA.

About Alitair Pharmaceuticals:

Alitair Pharmaceuticals, Inc. discovers, invents, and develops medicines for the treatment of respiratory illnesses. Alitair has out-licensed two prescription cough candidates that use its proprietary ion-exchange resin technology, REA™, and other product candidates are available for out-licensing. Additional information about Alitair is available on the Alitair website at www.alitair.com.

About Finn, Warnke & Gayton, LLP:

Joseph F. Finn, Jr. C.P.A., is the founding partner of Finn, Warnke & Gayton, LLP (www.finnwarnkegayton.com) Certified Public Accountants of Wellesley Hills, Massachusetts. For further information, please contact Chris Finn at 781-237-8840 or cfinn@finnwarnkegayton.com.